Clinical significance of chromosomal abnormality in multiple myeloma.
- Author:
Kyoung Tae KIM
1
;
Jeung Hoan PAIK
;
Chang Jae LEE
;
Jin Ho KIM
;
Yee Zee BAE
;
Bong Gun SEO
;
Hyuk Chan KWON
;
Sung Yong OH
;
Sung Hyun KIM
;
Jae Seok KIM
;
Jin Yeong HAN
;
Hyo Jin KIM
Author Information
1. Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea. kimhj@dau.ac.kr
- Publication Type:Case Report
- Keywords:
Multiple myeloma;
Chromosome;
Prognosis
- MeSH:
Arm;
B-Lymphocytes;
Chromosome Aberrations*;
Chromosomes, Human, Pair 13;
Creatinine;
Cytogenetic Analysis;
Cytogenetics;
Diagnosis;
Drug Therapy;
Follow-Up Studies;
Humans;
Karyotype;
Metaphase;
Multiple Myeloma*;
Plasma Cells;
Population Characteristics;
Prognosis
- From:Korean Journal of Medicine
2005;69(3):304-312
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Multiple myeloma is a clonal B-cell malignancy manifested by the accumulation of terminally differentiated plasma cells. The disease is characterized by clinical heterogeneity, with survival ranging from a few months to more than 10 years. The purpose of this study is to evaluate the prognostic value of specific chromosomal abnormality in multiple myeloma. METHODS: We analyzed the clinical records of 40 patients who were diagnosed as multiple myeloma, between April, 1995 and August, 2004. Cytogenetic analysis was conducted by metaphase karyotype analysis. Patients were grouped into normal cytogenetic group (arm A), complete or partial deletion of chromosome 13 and hypodiploidy group (arm B) and other cytogenetic abnormality group (arm C). RESULTS: Median follow up duration was 13.1 months (range 1.5-92.1). Overall response rate to chemotherapy was 58.8% and response rate among arm A, B and C were 56.3%, 33.3% and 75%, respectively (p=0.229). The prognostic factors affecting survival were clinical stage, performance status, serum creatinine level, sex and chromosomal abnormality. The median overall survival was significantly different among arm A, B and C (34.9 months, 8.5 months and 19.8 months, respectively, p=0.0125). CONCLUSION: chromosomal abnormality, especially, complete or partial deletion of chromosome 13 and hypodiploidy at initial diagnosis is significantly associated with survival duration.
